S'abonner

Selected recent advances in understanding the role of human mast cells in health and disease - 03/06/22

Doi : 10.1016/j.jaci.2022.01.030 
Francesca Levi-Schaffer, PharmD, PhD a, , Bernhard F. Gibbs, PhD b, Jenny Hallgren, PhD c, Carlo Pucillo, MD d, Frank Redegeld, PhD e, Frank Siebenhaar, MD f, g, Joana Vitte, PhD h, i, Soraya Mezouar, PhD j, Moïse Michel, PharmD h, k, Pier Giorgio Puzzovio, MS a, Marcus Maurer, MD f, g,
a Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel 
b Department of Human Medicine, University of Oldenburg, Oldenburg, Germany 
c Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden 
d Laboratory of Immunology, Department of Medicine, University of Udine, Udine, Italy 
e Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands 
f Institute for Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany 
g Fraunhofer Institute for Translational Medicine and Pharmacology, ITMP Allergology and Immunology, Berlin, Germany 
h Aix-Marseille University, IRD, APHM, MEPHI, Marseille, France 
i IDESP, INSERM UA 11, Montpellier, France 
j Aix-Marseille University, IRD, MEPHI, Marseille, France 
k Immunology Laboratory, CHU Nîmes, Nîmes, France 

Corresponding author: Francesca Levi-Schaffer, PharmD, PhD, Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O.B. 12272, Jerusalem 91120, Israel.Pharmacology and Experimental Therapeutics UnitInstitute for Drug ResearchSchool of PharmacyFaculty of MedicineThe Hebrew University of JerusalemP.O.B. 12272Jerusalem91120Israel∗∗Marcus Maurer, MD, Institute for Allergology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany.Institute for AllergologyCharité – Universitätsmedizin BerlinCharitéplatz 1BerlinD-10117Germany

Abstract

Mast cells are highly granular tissue-resident cells and key drivers of inflammation, particularly in allergies as well as in other inflammatory diseases. Most mast cell research was initially conducted in rodents but has increasingly shifted to the human system, with the advancement of research technologies and methodologies. Today we can analyze primary human cells including rare subpopulations, we can produce and maintain mast cells isolated from human tissues, and there are several human mast cell lines. These tools have substantially facilitated our understanding of their role and function in different organs in both health and disease. We can now define more clearly where human mast cells originate from, how they develop, which mediators they store, produce de novo, and release, how they are activated and by which receptors, and which neighboring cells they interact with and by which mechanisms. Considerable progress has also been made regarding the potential contribution of mast cells to disease, which, in turn, has led to the development of novel approaches for preventing key pathogenic effects of mast cells, heralding the era of mast cell–targeted therapeutics. In this review, we present and discuss a selection of some of the most significant advancements and remaining gaps in our understanding of human mast cells during the last 25 years, with a focus on clinical relevance.

Le texte complet de cet article est disponible en PDF.

Key words : Allergy, cancer, human mast cells, receptors, signal transduction

Abbreviations used : AT, BTK, DC, EMR2, Eos, ERK, FcεRI, MC, MCp, MRGPRX2, PAR-2, SHR, Siglec, SYK, TLR


Plan


 F.L.-S. received funding from the Rosetrees Trust (UK), Aimwell Charitable Trust (UK), Israel Science Foundation (grant no. 442/18), Israel Ministry of Science & Technology, and Emalie Gutterman Memorial Endowed Fund for COPD Related Research (USA). F.L.S. is affiliated with the Adolph and Klara Brettler Center for Molecular Pharmacology and Therapeutics at the School of Pharmacy of The Hebrew University of Jerusalem. J.H. received funding from the Swedish Research Council, Swedish Heart-Lung Foundation, Knut and Alice Wallenberg Foundation, Malin and Lennart Philipson Foundation, Konsul ThC Bergh’s Foundation, Hans von Kantzow Foundation, Ruth och Nils-Erik Stenbäck Foundation, and Mary Kay Foundation. J.V. received personal funding as associate professor from Aix-Marseille University, Faculty of Medicine, Marseille, France, MEPHI, IHU Méditerranée Infection, Marseille, France, and University Hospitals of Marseille, Marseille, France; is a nonpaid visiting researcher at IDESP INSERM UMR UA 11, University of Montpellier, Montpellier, France; and received research grants from Fondation de France/Agence Nationale pour la Recherche, IHU Méditerranée Infection, French Society of Allergology, and European Academy of Allergy and Clinical Immunology. S.M. received personal funding as a researcher from Aix-Marseille University, Marseille, France. M.M. received personal funding as an associate practitioner from University Hospitals of Nimes, Nîmes, France.
 Disclosure of potential conflict of interest: F. Siebenhaar is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Blueprint, Celldex, CogentBio, Genentech, Novartis, Moxie, Sanofi, and Uriach. J. Vitte reports speaker and consultancy fees in the past 5 years from Meda Pharma (Mylan), Novartis, Sanofi, and Thermo Fisher Scientific, outside the submitted work. M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Amgen, Aralez, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GIInnovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Roche, Sanofi/Regeneron, Third HarmonicBio, UCB, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 149 - N° 6

P. 1833-1844 - juin 2022 Retour au numéro
Article précédent Article précédent
  • Autoimmune chronic spontaneous urticaria
| Article suivant Article suivant
  • KIT as a master regulator of the mast cell lineage
  • Mindy Tsai, Peter Valent, Stephen J. Galli

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.